Hu *et al.*
BMC Complementary Medicine and Therapies (2023) 23:68
https://doi.org/10.1186/s12906-023-03865-5

BMC Complementary Medicine and Therapies

CORRECTION **Open Access**

Correction: Protective effects of Xinji′erkang on myocardial infarction induced cardiac injury in mice

Juan Hu[†], Yong-xue Zhang[†], Li Wang, Ling Ding, Guang-yao Huang, Guo-wei Cai and Shan Gao[*]

Correction: BMC Complement Med Ther 17, 338 (2017)
https://doi.org/10.1186/s12906-017-1846-5

Following publication of the original article [1], the authors identified an error in Fig. 3. The b4 of Fig. 3 in this published paper was wrongly used. The correct figure is given below.

The original article [1] has been corrected.

Published online: 04 March 2023

Reference

1. Hu J, Zhang Y, Wang L, et al. Protective effects of Xinji′erkang on myocardial infarction induced cardiac injury in mice. BMC Complement Altern Med. 2017;17:338. https://doi.org/10.1186/s12906-017-1846-5.

[†]Juan Hu and Yong-xue Zhang contributed equally to this work.

The original article can be found online at https://doi.org/10.1186/s12906-017-1846-5.

*Correspondence:
Shan Gao
aydgs@126.com
Department of Pharmacology, Basic Medical College, Anhui Medical University, Hefei 230032, China



Fig. 3 Effect of XJEK on cardiomyocyte CSA and cardiomyocyte long axis of MI mice (HE stain, magnification × 400). **a** Representative images of histological section of cardiomyocyte cross-section (HE staining, magnification × 400); **b** Representative images of histological section of cardiomyocyte long axis (HE staining, magnification × 400); **c** Quantitative analyses results (mean ± SEM, n=6–9). (1) Sham group; (2) Model group; (3) XJEK group; (4) Fosinopril group. $^{*}P<0.05$, $^{**}P<0.01$ *vs*. Sham group; $^{\#}P<0.05$, $^{\#\#}P<0.01$ *vs.* Model group